The Impact of Preoperative Low Body Mass Index on Postoperative Complications and Long-term Survival Outcomes in Gastric Cancer Patients.
- Author:
Chang Hyun KIM
1
;
Seung Man PARK
;
Jin Jo KIM
Author Information
- Publication Type:Original Article
- Keywords: Stomach neoplasms; Body mass index; Obesity; Underweight
- MeSH: Body Mass Index*; Humans; Obesity; Postoperative Complications*; Recurrence; Risk Factors; Stomach Neoplasms*; Thinness
- From:Journal of Gastric Cancer 2018;18(3):274-286
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study was to investigate the impact of preoperative low body mass index (BMI) on both the short- and long-term outcomes in patients with gastric cancer. MATERIALS AND METHODS: A total of 510 patients with gastric cancer were divided into the following 3 groups: low BMI group (≤18.5 kg/m2, n=51), normal BMI group (18.6–24.9 kg/m2, n=308), and high BMI group (≥25.0 kg/m2, n=151). RESULTS: There were significantly more stage III/IV patients in the low BMI group than in the other groups (P=0.001). Severe postoperative complications were more frequent (P=0.010) and the survival was worse (P < 0.001) in the low BMI group. The subgroup analysis indicated that survival was worse in the low BMI group of the stage I/II subgroup (P=0.008). The severe postoperative complication rate was higher in the low BMI group of the stage III/IV subgroup (P=0.001), although the recurrence rate and survival did not differ in the stage III/IV subgroup among all the BMI groups. Low BMI was an independent poor prognostic factor in the stage I/II subgroup (disease-free survival: hazard ratio [HR], 13.521; 95% confidence interval [CI], 1.186–154.197; P=0.036 and overall survival: HR, 5.130; 95% CI, 1.644–16.010; P=0.005), whereas low BMI was an independent risk factor for severe postoperative complications in the stage III/IV subgroup (HR, 17.158; 95% CI, 1.383–212.940; P=0.027). CONCLUSIONS: Preoperative low BMI in patients with gastric cancer adversely affects survival among those with stage I/II disease and increases the severe postoperative complication rate among those with stage III/IV disease.
